Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zamerovimab, an antibody targeting Rabies Virus Spike Glycoprotein G.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Semzuvolimab, an antibody targeting CD4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rocatinlimab, an antibody targeting OX40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pulocimab, an antibody targeting VEGFR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Paridiprubart, an antibody targeting TLR4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nofazinlimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mazorelvimab, an antibody targeting Rabies Virus Spike Glycoprotein G.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Manfidokimab, an antibody targeting IL-4Ralpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Litifilimab, an antibody targeting BDCA2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ligufalimab, an antibody targeting CD47.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Izalontamab, an antibody targeting EGFR × HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ifinatamab, an antibody targeting B7-H3.